Genmab Just Dropped $8 Billion on a Drug You've Never Heard Of
Genmab is shelling out $8 billion for Dutch biotech Merus NV and its experimental cancer drug petosemtamab, a first-in-class bispecific antibody with eye-popping early data in head and neck cancer. It's one of the year's biggest biotech deals, and the real prize might be the technology platform hiding behind the headline asset.
The Biggest Bet in Antibody Land
Eight billion dollars buys you a lot of things. A small country's GDP. Two NFL franchises. Or, if you're Danish antibody giant Genmab, one Dutch biotech company and its experimental cancer drug.
Genmab agreed to acquire Merus NV for $8 billion in cash, paying $97 per share in an all-cash tender offer. That's a 41% premium over where Merus was trading before the news broke, and roughly 44% above its 30-day average price of $67.42. The deal is being funded through a combination of cash on hand and $5.5 billion in new debt, with Morgan Stanley backing the financing commitment.
So what's worth mortgaging the house for? A bispecific antibody called petosemtamab that could reshape how doctors treat one of the nastiest forms of cancer.
What Petosemtamab Actually Does
Think of most cancer drugs as snipers: they aim at one target on a tumor cell and fire. Petosemtamab is more like a player who can guard two opponents at once. It's a bispecific antibody, meaning it latches onto two different proteins simultaneously: EGFR, a well-known growth signal in cancer, and LGR5, a marker found on cancer stem cells.
Why does that matter? Cancer stem cells are the cockroaches of oncology. Kill the bulk of a tumor, and these cells can survive and regrow it. By hitting both EGFR and LGR5 at the same time, petosemtamab attacks the tumor's growth engine and its ability to regenerate. It's the first drug of its kind to try this dual approach.
The primary target is head and neck squamous cell carcinoma (HNSCC), a cancer that affects around 900,000 people globally each year and has notoriously limited treatment options once it spreads.
The Numbers That Got Genmab's Attention
Petosemtamab is still in mid-stage trials, but the early data has been turning heads at oncology conferences.
As a standalone treatment in patients whose cancer had already returned or spread, petosemtamab produced a across 75 patients. Median overall survival hit . For a cancer this aggressive, those are genuinely encouraging numbers.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
36% response rate
11.5 months
But the combination data is where things get really interesting. When paired with pembrolizumab (Merck's blockbuster Keytruda) in first-line PD-L1-positive patients, the response rate jumped to 63%, including one complete response among efficacy-evaluable patients. Complete response means the cancer became undetectable on scans. That's the kind of data that makes pharma executives reach for their checkbooks.
Phase 3 trials (the final stage before seeking approval) are already underway through a program called LiGeR-HN, testing petosemtamab-based regimens in both first-line and later-line HNSCC. Overall survival is one of the primary endpoints, which signals confidence from the development team.
More Than a One-Trick Pony
If Genmab were paying $8 billion for a single drug, you might raise an eyebrow. But Merus brings something arguably more valuable: a technology platform called Biclonics.
Biclonics is Merus's proprietary system for building bispecific antibodies. Think of it as a factory that can design antibodies to grab any two targets you want. Merus also developed extensions called Triclonics and Multiclonics that can hit three or more targets simultaneously.
Before the acquisition, Merus had already parlayed this platform into collaborations with some of pharma's biggest names. Gilead signed on for trispecific T-cell engagers (antibodies that recruit immune cells to attack cancer from three angles). Eli Lilly's oncology arm, Loxo, partnered on up to three CD3-engaging bispecific therapies. And Biohaven teamed up for bispecific antibody-drug conjugates, a hot area combining targeted antibodies with cell-killing payloads.
For Genmab, which built its reputation on its own antibody engineering platform called DuoBody, absorbing Biclonics is like a chef adding an entire second kitchen to their restaurant. More tools, more recipes, more ways to cook.
Genmab's Bigger Game Plan
This deal doesn't exist in a vacuum. Genmab has been on an acquisition spree to transform itself from a hematology-focused (blood cancer) company into a full-spectrum oncology powerhouse.
The company previously acquired ProfoundBio to get its hands on Rina-S, a next-generation antibody-drug conjugate targeting ovarian and other solid tumors. Combined with epcoritamab (its approved blood cancer treatment) and now petosemtamab, Genmab has assembled a three-headed monster of late-stage oncology assets.
Notably, Genmab has been trimming its earlier-stage programs to funnel resources into these high-conviction bets. That's a company that knows where it wants to go and isn't afraid to cut the dead weight to get there.
The Competitive Chessboard
The bispecific antibody space has become one of biotech's most crowded arenas. Trial starts peaked in 2025, and the most popular target combinations (PD-1/VEGF, CTLA-4/PD-1) are getting so crowded that differentiation now comes down to safety profiles and dosing convenience rather than novelty.
That's actually what makes petosemtamab compelling. The EGFR/LGR5 combination is first-in-class, meaning nobody else is running this play. In a sea of me-too bispecifics chasing the same targets, Genmab just bought something genuinely different.
Big pharma has been using M&A to lock down access to the bispecific modality rather than building from scratch. Genmab's move fits squarely in that trend, but the size of the check ($8 billion makes this one of the year's largest biotech acquisitions) reflects just how high the stakes have gotten.
The Risk Nobody Wants to Talk About
The elephant in the room: petosemtamab's most impressive data is still phase 2, based on relatively small patient groups. Phase 2 results are the movie trailer; phase 3 is the actual film. Plenty of promising cancer drugs have stumbled when tested in larger, more rigorous trials.
Genmab is also taking on $5.5 billion in debt to close this deal, which is a significant financial burden for a company that, while profitable, isn't exactly swimming in Pfizer-level cash flows. If the phase 3 trials disappoint, that debt doesn't disappear.
Still, the logic is hard to argue with. A first-in-class bispecific with strong early data, a versatile antibody platform with multiple partnerships already generating value, and a strategic fit with Genmab's existing capabilities. Sometimes the best deals are the ones where you pay a premium now to avoid paying a bigger one later.
The tender offer has been completed and Merus shares have been delisted. The marriage is official. Now comes the hard part: proving that $8 billion was a bargain.
4 min read
GSK Thinks It Can Build a Better Flu Shot With mRNA
GSK's mRNA flu vaccine just beat both standard and high-dose flu shots in a mid-stage trial of 971 adults. Now it's heading to Phase 3, putting GSK squarely in Moderna's rearview mirror in the race to reinvent the annual flu shot.
